Nexentis Technologies Inc.

Nexentis Technologies Inc., through its subsidiary, develops therapeutics for cancer and inflammatory metabolic diseases. The company operates through two segments: Biotechnology Activity and Renewable Energy Projects. Its product pipeline includes MITOLINE, an algorithm designed for multiple sequence/structure pairwise alignments to generate 3D comparative models of mitochondrial carrier proteins. The company also offers a cloud-based computational chemistry platform, novel in-vitro screening platforms, and advanced 3D NSCLC tumor spheroid systems. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel. The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026.